Benzodiazepine-Based Drug Discovery - Farzad Zamani, Esmail Doustkhah

Benzodiazepine-Based Drug Discovery

Buch | Softcover
338 Seiten
2022
Elsevier Science Publishing Co Inc (Verlag)
978-0-12-824516-3 (ISBN)
218,20 inkl. MwSt
Benzodiazepine-Based Drug Discovery covers benzodiazepines and benzothiazepines, which constitute two pivotal classes of heterocyclic compounds widely used as core structures of medicinal drugs for the treatment of depression, epilepsy, seizures and muscle spasms. 1,4-Benzodiazepine, 1,5-benzodiazepine, and 1,5-benzothiazepine are the most studied groups of benzodiazepines and benzothiazepines because of their outstanding potential biological activities. This book offers a broad range of recent developments and detailed coverage of the synthesis and biological activities of the drugs based on benzodiazepine and benzothiazepine matrixes, and is an ideal reference guide to researchers working in organic and medicinal chemistry.

The importance of these privileged pharmacophores is not limited to the treatment of psychotic disorders because minor changes in the structures can generate various biological activities. They represent a wide range of therapeutic functions such as anticonvulsant, antianxiety, anti-depressant, antiviral, anti-HIV, anti-inflammatory, anticoagulant, anti-obesity, endothelin antagonist, cholecystokinin antagonist, and vasopressin receptor antagonist activities.

Farzad Zamani obtained his PhD from University of Wollongong (Australia) in 2019 under the supervision of Professor Stephen Pyne and Dr. Christopher Hyland. His research included development of transition metal-catalyzed cyclization reactions and heterocycle synthesis. Currently, he is a JSPS postdoctoral fellow in the group of Professor Takayoshi Suzuki at Osaka University working on investigation of small molecule inhibitors of RNA/epigenetic protein complexes in drug discovery.Farzad Zamani obtained his PhD from University of Wollongong (Australia) in 2019 under the supervision of Professor Stephen Pyne and Dr. Christopher Hyland. His research included development of transition metal-catalyzed cyclization reactions and heterocycle synthesis. Currently, he is a JSPS postdoctoral fellow in the group of Professor Takayoshi Suzuki at Osaka University working on investigation of small molecule inhibitors of RNA/epigenetic protein complexes in drug discovery. Esmail Doustkhah received his PhD in 2017 in the field of catalysis and organic chemistry. In his PhD, he received several awards and scholarships. Currently, he is a JSPS fellow at NIMS in the group of Professors Y. Yamauchi and Y. Ide. His research areas include silicate nanosheet, mesoporous materials, and titania nanostructures for (photo)(bio)catalysis.

1. An Introduction to Benzodiazepines 2. Chemical Structure of 1,4-Benzodiazepines 3. Synthesis of 1,4-Benzodiazepines 4. Biological Behavior of 1,4-Benzodiazepines 5. Pharmaceutical Applications of 1,4-Benzodiazepines 6. Chemical Structure of 1,5-Benzodiazepines and 1,5-Benzothiazepines 7. Synthesis of 1,5-Benzodiazepines and 1,5-Benzothiazepines 8. Biological Behavior of 1,5-Benzodiazepines and 1,5-Benzothiazepines 9. Pharmaceutical Applications of 1,5-Benzodiazepines 10. Pharmaceutical Applications of 1,5-Benzothiazepines

Erscheinungsdatum
Reihe/Serie Heterocyclic Drug Discovery
Zusatzinfo Approx. 100 illustrations; Illustrations
Sprache englisch
Maße 152 x 229 mm
Gewicht 540 g
Themenwelt Naturwissenschaften Chemie Organische Chemie
ISBN-10 0-12-824516-6 / 0128245166
ISBN-13 978-0-12-824516-3 / 9780128245163
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Deluxe Edition

von K. P. C. Vollhardt; Neil E. Schore; Holger Butenschön

Buch | Hardcover (2020)
Wiley-VCH (Verlag)
119,00